Source comparison
Tesamorelin HIV Lipodystrophy: Treatment Comparison
Patients and clinicians often weigh tesamorelin against alternative interventions for managing HIV lipodystrophy. The table below compares efficacy, mechanism, durability, and practical considerations across available options. Tesamorelin 2mg daily GHRH analog
This comparison does not assign a generated winner or score.
- Patients and clinicians often weigh tesamorelin against alternative interventions for managing HIV lipodystrophy. The table below compares efficacy, mechanism, durability, and practical considerations across available options.
- Tesamorelin 2mg daily
- GHRH analogue stimulating endogenous GH release; preferential visceral lipolysis
- 15-20% at 26 weeks
- Reverses within 12 weeks
- Modest triglyceride reduction; glucose elevation risk in 10-15%
- Only FDA-approved pharmacological option; requires indefinite use but most effective for VAT reduction
- Dietary caloric restriction + exercise
- Energy deficit promoting total body fat loss (non-selective)
- 0-5% VAT; often worsens peripheral wasting
- Not applicable. Lifestyle-dependent
- Improves insulin sensitivity if sustained; difficult to maintain
- Ineffective for VAT-specific reduction in lipodystrophy; may worsen lipoatrophy in limbs
- Liposuction (surgical)
- Mechanical removal of subcutaneous fat
- 0% VAT (cannot access intra-abdominal depots)
- Permanent removal of subcutaneous fat only
- No metabolic benefit; does not address VAT
- Cosmetic only; does not treat underlying metabolic syndrome
- ART regimen switch (to newer integrase inhibitors)
- Removal of mitochondrial-toxic agents (older PIs, NRTIs)
- Variable; may slow progression but rarely reverses established VAT
- Requires permanent regimen change
- May improve lipid profile and insulin sensitivity
- Preventive strategy; limited efficacy for reversing existing lipodystrophy
- Exogenous GH (off-label)
- Direct GH replacement; supraphysiological IGF-1 elevation
- 10-15% at 6 months
- Reverses within 8-12 weeks
- Higher glucose intolerance risk; acromegalic features possible
- Not FDA-approved for this indication; greater adverse event risk than tesamorelin
- The comparison makes clear that tesamorelin HIV lipodystrophy treatment occupies a unique position. It is the only intervention that selectively reduces visceral adipose tissue through a physiological mechanism while preserving subcutaneous fat and lean mass.